Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CYTH2 | Q99418 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160443 | 0.93 | CYTH2 (0.54) | ALDH1A1LMNACYTH2GAAFFAR4 | |
| SCHEMBL10623079 | 0.82 | FFAR4 (0.70) | CYTH2FFAR4HSP90AA1CRHBPCRHR2 | |
| SCHEMBL2434886 | 0.81 | GAA (0.55) | ALDH1A1LMNACYTH2GAAFFAR4 | |
| SCHEMBL2437807 | 0.79 | CYTH2 (0.54) | ALDH1A1LMNACYTH2GAAFFAR4 | |
| SCHEMBL9164476 | 0.79 | NLRP3 (0.67) | ALDH1A1LMNACYTH2GAAFFAR4 | |
| SCHEMBL5158966 | 0.76 | CYTH2 (0.57) | ALDH1A1LMNACYTH2GAAFFAR4 | |
| SCHEMBL27876169 | 0.75 | HSP90AA1 (0.50) | ALDH1A1LMNACYTH2GAAFFAR4 | |
| SCHEMBL6577363 | 0.74 | CA2 (0.71) | ALDH1A1LMNACYTH2GAACYP3A4 | |
| SCHEMBL2243826 | 0.74 | CA2 (0.71) | ALDH1A1LMNACYTH2GAACYP3A4 | |
| SCHEMBL10655906 | 0.74 | CRHBP (0.66) | ALDH1A1LMNAGAAFFAR4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102516204-B | The morpholine replaced and thiomorpholine derivatives | H. LUNDHECK A/S (DK) | 2016-01-20 | — | — | CN | disclosed |
| US-8299075-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2012-10-30 | — | — | US | disclosed |
| CN-102516204-A | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H | 2012-06-27 | — | — | CN | disclosed |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2011-12-01 | — | — | US | disclosed |
| US-8012962-B2 | Substituted thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2011-09-06 | — | — | US | disclosed |
| US-7812023-B2 | Methods of using substituted morpholine derivatives | H. LUNDBECK A/S (DK) | 2010-10-12 | — | — | US | disclosed |
| US-20100063033-A1 | Methods of using substituted morpholine derivatives | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| US-20100063036-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2010-03-11 | — | — | US | disclosed |
| EP-1947093-B9 | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2010-03-03 | — | — | EP | disclosed |
| EP-2138487-A1 | Substituted morpholine and thiomorpholine derivatives for the treatment of bipolar disorders | H. Lundbeck A/S (DK) | 2009-12-30 | — | — | EP | disclosed |
| US-7501414-B2 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2009-03-10 | — | — | US | disclosed |
| EP-1727809-B8 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-10-29 | — | — | EP | disclosed |
| EP-1947093-A1 | Substituted morpholine and thiomorpholine derivatives | H. Lundbeck A/S (DK) | 2008-07-23 | — | — | EP | disclosed |
| EP-1727809-B1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | LUNDBECK & CO AS H (DK) | 2008-06-11 | — | — | EP | disclosed |
| CN-1930138-A | Substituted morpholine and thiomorpholine derivatives | LUNDBECK & CO AS H (DK) | 2007-03-14 | — | — | CN | disclosed |
| EP-1727809-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H.Lundbeck A/S (DK) | 2006-12-06 | — | — | EP | disclosed |
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| WO-2005087754-A1 | SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2005-09-22 | — | — | WO | disclosed |
| US-5442060-A | Treating hyperlipemia, atherosclerosis | MITSUBISHI KASEI CORPORATION (JP) | 1995-08-15 | — | — | US | disclosed |
| EP-0591830-A1 | Carboxamide and urea derivatives having ACAT-inhibiting activityM | Mitsubishi Chemical Corporation (JP) | 1994-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167248-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | ALDH1A1 1668/4885LMNA 4789/4885CYTH2 815/4885 |
| US-20100063033-A1 | Methods of using substituted morpholine derivatives | OPRM1, TPMT, SIGMAR1 | ALDH1A1 1464/4885LMNA 4533/4885CYTH2 770/4885 |
| US-20110294787-A1 | SUBSTITUTED THIOMORPHOLINE DERIVATIVES | OPRM1, OPRK1, OPRL1 | ALDH1A1 1483/4885LMNA 4865/4885CYTH2 1415/4885 |
| US-20100063036-A1 | Substituted morpholine and thiomorpholine derivatives | OPRM1, OPRK1, OPRD1 | ALDH1A1 1668/4885LMNA 4789/4885CYTH2 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.